The Clinicopathological and Prognostic Significance of MTOR and P-mTOR Expression in Patients with Non-small Cell Lung Cancer: A Meta-analysis

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2023 Jan 3

PMID 36595789

Authors

Weiwei Qiu

Meiying Ren

Cuifeng Wang

Yuhua Fu

Yan Liu

Affiliations

Soon will be listed here.

Abstract

Background: The mammalian target of rapamycin (mTOR) has a crucial role in carcinogenesis, angiogenesis, cellular proliferation, and metastasis; however, its significance in non-small cell lung cancer (NSCLC) remains contentious. Consequently, this study aims to assess the clinicopathological and prognostic importance of mTOR/p-mTOR expression in NSCLC.

Methods: Literature retrieval was undertaken by searching English databases PubMed, EMBASE, Web of Science, and Cochrane Library as well as Chinese databases CNKI, Wan Fang, and VIP for full-text publications that satisfied our eligibility criteria up to November 2021. STATA 12.0 was used to conduct statistical analysis (STATA Corporation, College Station, TX).

Results: This meta-analysis includes a total of 4683 patients from 28 primary publications. mTOR/p-mTOR expression was associated with sex (OR = 0.608, 95% CI: 0.442-0.836), lymph node metastasis (OR = 2.084, 95% CI: 1.437-3.182), and CEA (OR = 1.584, 95% CI: 1.135-2.209), but not with age, histological type, depth of tumor invasion, distant metastasis, TNM stage, differentiation degree, tumor size, or smoking. In addition, the expression of mTOR/p-mTOR is related to shorter overall survival in NSCLC patients (HR = 1.415, 95% CI: 1.051-1.905).

Conclusion: Positive mTOR/p-mTOR expression was substantially correlated with unfavorable conditions on the sex, lymph node metastases, and CEA levels. mTOR/p-mTOR may indicate a bad prognosis for NSCLC. The current findings must be confirmed and changed by other high-quality research employing a multivariate analysis on bigger sample size.

References

Zhang Y, Ni H, Cheng D . Prognostic value of phosphorylated mTOR/RPS6KB1 in non- small cell lung cancer. Asian Pac J Cancer Prev. 2013; 14(6):3725-8. DOI: 10.7314/apjcp.2013.14.6.3725. View

Mody R, Naranjo A, Van Ryn C, Yu A, London W, Shulkin B . Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. Lancet Oncol. 2017; 18(7):946-957. PMC: 5527694. DOI: 10.1016/S1470-2045(17)30355-8. View

Emons G, Kurzeder C, Schmalfeldt B, Neuser P, de Gregorio N, Pfisterer J . Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8). Gynecol Oncol. 2016; 140(3):450-6. DOI: 10.1016/j.ygyno.2015.12.025. View

Heitman J, Movva N, Hall M . Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science. 1991; 253(5022):905-9. DOI: 10.1126/science.1715094. View

Gately K, Al-Alao B, T Dhillon , Mauri F, Cuffe S, Seckl M . Overexpression of the mammalian target of rapamycin (mTOR) and angioinvasion are poor prognostic factors in early stage NSCLC: a verification study. Lung Cancer. 2011; 75(2):217-22. DOI: 10.1016/j.lungcan.2011.06.012. View

Ooft M, Braunius W, Heus P, Stegeman I, van Diest P, Grolman W . Prognostic significance of the EGFR pathway in nasopharyngeal carcinoma: a systematic review and meta-analysis. Biomark Med. 2015; 9(10):997-1010. DOI: 10.2217/bmm.15.68. View

Bose S, Chandran S, Mirocha J, Bose N . The Akt pathway in human breast cancer: a tissue-array-based analysis. Mod Pathol. 2005; 19(2):238-45. DOI: 10.1038/modpathol.3800525. View

Lu J, Zang H, Zheng H, Zhan Y, Yang Y, Zhang Y . Overexpression of p-Akt, p-mTOR and p-eIF4E proteins associates with metastasis and unfavorable prognosis in non-small cell lung cancer. PLoS One. 2020; 15(2):e0227768. PMC: 7001968. DOI: 10.1371/journal.pone.0227768. View

Yao J, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E . Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2015; 387(10022):968-977. PMC: 6063317. DOI: 10.1016/S0140-6736(15)00817-X. View

10.

Ding X, Li L, Zhou X, Guo L, Dou M, Chi Y . P-mTOR Expression and Implication in Breast Carcinoma: A Systematic Review and Meta-Analysis. PLoS One. 2017; 12(1):e0170302. PMC: 5256929. DOI: 10.1371/journal.pone.0170302. View

11.

Cai W, Shi Y, Zhao Q . [Relationship between expression of mTOR and prognosis of early stage non-small cell lung cancer]. Zhonghua Zhong Liu Za Zhi. 2014; 36(2):120-2. View

12.

Liu G, Pei F, Yang F, Li L, Amin A, Liu S . Role of Autophagy and Apoptosis in Non-Small-Cell Lung Cancer. Int J Mol Sci. 2017; 18(2). PMC: 5343902. DOI: 10.3390/ijms18020367. View

13.

Yoshizawa A, Fukuoka J, Shimizu S, Shilo K, Franks T, Hewitt S . Overexpression of phospho-eIF4E is associated with survival through AKT pathway in non-small cell lung cancer. Clin Cancer Res. 2009; 16(1):240-8. PMC: 7581274. DOI: 10.1158/1078-0432.CCR-09-0986. View

14.

Passaro A, Brahmer J, Antonia S, Mok T, Peters S . Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies. J Clin Oncol. 2022; 40(6):598-610. DOI: 10.1200/JCO.21.01845. View

15.

Soria J, Shepherd F, Douillard J, Wolf J, Giaccone G, Crino L . Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Ann Oncol. 2009; 20(10):1674-81. DOI: 10.1093/annonc/mdp060. View

16.

Nepstad I, Hatfield K, Gronningsaeter I, Aasebo E, Hernandez-Valladares M, Hagen K . Effects of insulin and pathway inhibitors on the PI3K-Akt-mTOR phosphorylation profile in acute myeloid leukemia cells. Signal Transduct Target Ther. 2019; 4:20. PMC: 6582141. DOI: 10.1038/s41392-019-0050-0. View

17.

Hynes N, Lane H . ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005; 5(5):341-54. DOI: 10.1038/nrc1609. View

18.

Gold K, Kim E, Liu D, Yuan P, Behrens C, Solis L . Prediction of survival in resected non-small cell lung cancer using a protein expression-based risk model: implications for personalized chemoprevention and therapy. Clin Cancer Res. 2013; 20(7):1946-54. PMC: 4018222. DOI: 10.1158/1078-0432.CCR-13-1959. View

19.

Quigley J, Thompson J, Halfpenny N, Scott D . Critical appraisal of nonrandomized studies-A review of recommended and commonly used tools. J Eval Clin Pract. 2018; 25(1):44-52. DOI: 10.1111/jep.12889. View

20.

Wang L, Yue W, Zhang L, Zhao X, Wang Y, Xu S . mTOR and PTEN expression in non-small cell lung cancer: analysis by real-time fluorescence quantitative polymerase chain reaction and immunohistochemistry. Surg Today. 2011; 42(5):419-25. DOI: 10.1007/s00595-011-0028-1. View